-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

Benzinga·09/09/2026 17:58:53
语音播报
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.